Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1441 to 1455 of 2006 results for nice guidelines

  1. Paclitaxel for the adjuvant treatment of early node-positive breast cancer (TA108)

    This guideline has been updated and replaced by NICE guideline NG101.

  2. Docetaxel for the adjuvant treatment of early node-positive breast cancer (TA109)

    This guideline has been updated and replaced by NICE guideline NG101.

  3. Bivalirudin for the treatment of ST-segment-elevation myocardial infarction (TA230)

    This guideline has been updated and replaced by NICE guideline NG185.

  4. Obesity: working with local communities (PH42)

    This guideline has been updated and replaced by NICE guideline NG246.

  5. Weight management: lifestyle services for overweight or obese children and young people (PH47)

    This guideline has been updated and replaced by NICE guideline NG246.

  6. Weight management: lifestyle services for overweight or obese adults (PH53)

    This guideline has been updated and replaced by NICE guideline NG246.

  7. Preventing excess weight gain (NG7)

    This guideline has been updated and replaced by NICE guideline NG246.

  8. Cellvizio confocal endomicroscopy system for characterising pancreatic cysts (MIB69)

    Advice on the use of Cellvizio confocal endomicroscopy system (CLS) for characterising pancreatic cysts to aid local decision-making

  9. Intrapartum care for healthy women and babies (CG190)

    This guideline has been updated and replaced by the NICE guideline on intrapartum care (NG235).

  10. COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital (NG173)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

  11. COVID-19 rapid guideline: acute kidney injury in hospital (NG175)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

  12. COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

  13. COVID-19 rapid evidence summary: Sarilumab for COVID-19 (ES34)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.